Anti-VEGF Receptor 2 抗体 (ab2349)
Key features and details
- Rabbit polyclonal to VEGF Receptor 2
- Suitable for: IHC-Fr, IHC-P, ICC/IF, Flow Cyt, IP
- Reacts with: Mouse, Rat, Cow, Dog, Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-VEGF Receptor 2 antibody
VEGF Receptor 2 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to VEGF Receptor 2 -
由来種
Rabbit -
アプリケーション
適用あり: IHC-Fr, IHC-P, ICC/IF, Flow Cyt, IPmore details -
種交差性
交差種: Mouse, Rat, Cow, Dog, Human -
免疫原
Synthetic peptide corresponding to Mouse VEGF Receptor 2 (C terminal).
-
ポジティブ・コントロール
- IHC-P: Human normal breast and angiosarcoma tissues; Mouse skin tissue.
-
特記事項
Isoform 1 localization: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome.
Note: Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.3
Preservative: 0.05% Sodium azide
Constituent: 1% BSA -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab2349の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-Fr |
Use at an assay dependent concentration.
|
|
IHC-P | (7) |
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
ICC/IF | (8) |
Use at an assay dependent concentration.
See Abreview. |
Flow Cyt |
Use at an assay dependent concentration. PubMed: 18602918
ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody. |
|
IP |
Use at an assay dependent concentration.
|
特記事項 |
---|
IHC-Fr
Use at an assay dependent concentration. |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ICC/IF
Use at an assay dependent concentration. See Abreview. |
Flow Cyt
Use at an assay dependent concentration. PubMed: 18602918 ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody. |
IP
Use at an assay dependent concentration. |
ターゲット情報
-
機能
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
関連疾患
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
配列類似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
翻訳後修飾
Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 3791 Human
- Entrez Gene: 16542 Mouse
- Entrez Gene: 25589 Rat
- Omim: 191306 Human
- SwissProt: P35968 Human
- SwissProt: P35918 Mouse
- SwissProt: O08775 Rat
- Unigene: 479756 Human
see all -
別名
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
画像
-
Formalin fixed, paraffin-embedded human angiosarcoma tissue stained for VEGF Receptor 2 using ab2349 at 1/50 dilution in immunohistochemical analysis.
-
ab2349 staining the VEGF Receptor 2 in Mouse skin tissue sections by Immunohistochemistry (IHC-P - formaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 hour at room temperature; antigen retrieval was by heat mediation in citrate buffer (pH 6). Samples were incubated with primary antibody (1/100 in PBS + 2% blocking serum) for 16 hours at 4°C. A biotin-conjugated Goat anti-rabbit IgG polyclonal (1/250) was used as the secondary antibody.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human normal breast tissue labeling VEGF Receptor 2 with ab2349 at 1/200 dilution. Sections were lightly counterstained with hematoxylin.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human normal breast tissue labeling VEGF Receptor 2 with ab2349 at 1/200 dilution. Sections were lightly counterstained with hematoxylin.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (128)
ab2349 は 128 報の論文で使用されています。
- Merikhian P et al. Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors. Mol Oncol 16:485-507 (2022). PubMed: 34694686
- Kimura M et al. Comparison of vascular endothelial growth factor/vascular endothelial growth factor receptor 2 expression and its relationship to tumor cell proliferation in canine epithelial and mesenchymal tumors. J Vet Med Sci 84:133-141 (2022). PubMed: 34819426
- Li J et al. Swimming attenuates tumor growth in CT-26 tumor-bearing mice and suppresses angiogenesis by mediating the HIF-1α/VEGFA pathway. Open Life Sci 17:121-130 (2022). PubMed: 35291563
- Zhang G et al. Radix Astragalus Polysaccharide Accelerates Angiogenesis by Activating AKT/eNOS to Promote Nerve Regeneration and Functional Recovery. Front Pharmacol 13:838647 (2022). PubMed: 35431954
- Nakahama K et al. Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer. Cancer Sci 113:3148-3160 (2022). PubMed: 35722982